Nav: Home

Right-sided colon cancer patients have poorer survival than those with left-sided disease

July 23, 2018

ORLANDO (July 23, 2018): Patients with colorectal cancer tumors on the right side may have poorer five-year survival rates than those whose tumors are located on the left side. However, a new large-scale retrospective study is the first to demonstrate a potential improvement of these outcomes. Study results show that nearly doubling the benchmark number of lymph nodes removed during operations for right-sided colon cancers improves the survival rate for these patients, according to researchers who presented these findings at the 2018 American College of Surgeons (ACS) Quality and Safety Conference.

Several studies in recent years have shown that patients with colon cancers on the right side have worse short- and long-term survival rates than those with left-sided tumors regardless of the stage of the disease at diagnosis or the nature of treatment.1 Additional studies have begun to re-examine the surgical management of patients with right-sided colon cancer.2

For years the consensus among professional surgical and cancer treatment societies has held that, at a minimum, 12 lymph nodes should be removed and analyzed to determine the prognosis and treatment of patients with colon cancer on either side. The ACS Commission on Cancer (CoC) has identified this standard as a quality performance indicator for surgical treatment.3 As presented at the ACS conference, these study results are the first to link improved survival with a harvest of more than 20 lymph nodes in the treatment of right-sided cancer.

Investigators from Florida Hospital, Orlando, and McGill University Health Centre, Montreal, Quebec, collected information from the National Cancer Database (NCDB) about patients who underwent surgical removal of the colon for non-metastatic colon adenocarcinoma between 2004 and 2014. After adjusting for patient and disease characteristics as well as the type of systemic treatment, researchers grouped data by tumor location. Of a total of approximately 505,000 patients whose records were entered into the NCDB, 273,200 had right-sided tumors.

Overall five-year survival for this group of patients with right-sided tumors was 66 percent for stage II disease and 56 percent for stage III cancer. In comparison, survival rates were 70 percent and 60 percent for patients with left-sided stage II and III cancers. Among patients with right-sided cancer, the survival rate improved by approximately 20 percent when 22 or more lymph nodes were harvested during patients' operations.

Findings from the study suggest that colorectal surgeons may want to take extra steps to improve lymph node harvest for patients with right-sided disease. Colorectal surgeons from Florida Hospital and McGill University Health Centre are using near-infrared fluorescent scanning to map the lymph node drainage basins around tumors to potentially better identify lymph node metastases.

"We're injecting tumors with indocyanine green dye so we can find suspicious lymph nodes. During surgical resection, we're specifically targeting those extra nodes to get better staging," said study author Lawrence Lee, MD, PhD, a colorectal surgeon and PhD in epidemiology at McGill University Health Centre.

The study also may prompt surgeons to begin reexamining the type of operations they perform on patients with right-sided colorectal tumors.

"Lymph node harvest is related to the extent of the surgical resection. If removal of more lymph nodes improves survival of patients with right-sided cancer, these patients may need a more extensive resection than is considered to be standard for them," Dr. Lee said.

Operations currently differ for left- and right-sided colon cancers. The standard procedure for patients with left-sided cancers involves high central vascular ligation (CVL) of major blood vessels up near the aorta. CVL is not usually done for patients with right-sided cancers because the abdominal anatomy and vascular networks are complicated and operating around them increases operative time and the risk of complications.4

Surgical teams in Asia and Europe have recently reported on small, single-center studies of laparoscopic or robotic extended right-sided resections with CVL that did not increase operative time or complication rate and improved short- and long-term outcomes.5

"The kinds of vascular ligations that are required to get a greater nodal harvest on the right side mean the surgeon is dissecting around really big blood vessels. It's a larger resection overall on that side, and the more vasculature that's involved, the higher the risk for anastomotic breakdown and injury to these blood vessel. So surgeons may not want to do more resection on right-sided colon cancers," said Dr. Lee.

A multicenter, randomized prospective study is required to establish the value of an extended resection and CVL on the right side. As Dr. Lee acknowledged, "We don't know the answer to the risk/reward ratio, but our study shows there's enough of a difference in survival with greater surgical resection that we need a better understanding of the way we're operating on the right side."
Other study investigators include Arman Erkan, MD; Justin J. Kelly MD; George J Nassif, DO, FACS; Matthew R Albert MD, FACS; John RT Monson MD, FACS; from Florida Hospital, and Noura Alhassan MD, from McGill University Health Centre.

Research results were presented at the American College of Surgeons 2018 Quality and Safety Conference in Orlando, Fla., July 21-24, 2018.

"FACS" indicates that a surgeon is a Fellow of the American College of Surgeons.

1 Petrelli F, Prognostic Survival Associated with Left-Sided vs. Right-Sided Colon Cancer. A Systematic Review and Meta-Analysis. JAMA Oncol 2017; 3(2):211-19.

2 Shia J. Lymph Node Staging in Colorectal Cancer: Revisiting the Benchmark of at Least 12 Lymph Nodes in R0 Resection. JACS 2012, 214(3) 348-355.

3 CoC Quality of Care Measures. American College of Surgeons. Available at: Accessed July 2, 2018.

4 Yee LF. What Is a Complete Mesocolic Excision for Colon Cancer. California Pacific Medical Center, Nafziger Society Surgery Day, Mar 7, 2014.

5 Petz W, et al. Suprapubic Approach for Robotic Complete Mesocolic Excision in Right Colectomy: Oncologic Safety and Short-Term Outcomes of an Original Technique. Eur J Surg Oncol, 2017, Nov:43 (11)2060-2066. An MS, et al. Oncological Outcomes of Complete Versus Conventional Mesocolic Excision in Laparoscopic Right Hemicolectomy. ANZ J Surg 2018, Jun 12, doe:10.1111.ans.14493. S Du, et al. A novel and Safe Approach: Middle Cranial Approach for Laparoscopic Right Hemicolon Cancer Surgery with Complete Mesocolic Excision. Surg Endosc 2018 May;32(5):2567-74.

About the American College of Surgeons

The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for all surgical patients. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 80,000 members and is the largest organization of surgeons in the world. For more information, visit

About the National Cancer Database (NCDB)

The nationally recognized National Cancer Database (NCDB)--jointly sponsored by the American College of Surgeons and the American Cancer Society--is a clinical oncology database sourced from hospital registry data that are collected in more than 1,500 Commission on Cancer (CoC)-accredited facilities. NCDB data are used to analyze and track patients with malignant neoplastic diseases, their treatments, and outcomes. Data represent more than 70 percent of newly diagnosed cancer cases nationwide and more than 34 million historical records.

American College of Surgeons

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...